Metabotropic glutamate receptor 5-negative allosteric modulators for the treatment of psychiatric and neurological disorders (2009–July 2013)

By Li Guiying   Jørgensen Morten   Campbell Brian M  

Pharmaceutical Patent Analyst, Vol. 2, Iss. 6, 2013-11 ,pp. : 767-802

Future Science

Access to resources Recommend Favorite

AMPA Receptor Positive Allosteric Modulators: Potential for the Treatment of Neuropsychiatric and Neurological Disorders

By  

Current Topics in Medicinal Chemistry, Vol. 16, Iss. 29, 2016-12 ,pp. : 3536-3565

Bentham Science Publishers

Access to resources Recommend Favorite

Group I Metabotropic Glutamate Receptor Signalling and its Implication in Neurological Disease

By  

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 9, Iss. 5, 2010-11 ,pp. : 574-595

Bentham Science Publishers

Access to resources Recommend Favorite

Progress in the Developement of Positive Allosteric Modulators of the Metabotropic Glutamate Receptor 2

By  

Current Medicinal Chemistry, Vol. 18, Iss. 1, 2011-01 ,pp. : 47-68

Bentham Science Publishers

Access to resources Recommend Favorite

Metabotropic glutamate receptor 4 (mGlu₄)-positive allosteric modulators for the treatment of Parkinson's disease: historical perspective and review of the patent literature

By Lindsley Craig W   Hopkins Corey R  

Expert Opinion on Therapeutic Patents, Vol. 22, Iss. 5, 2012-05 ,pp. : 461-481

Informa Healthcare

Access to resources Recommend Favorite